We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
-19.74%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$2B
AUM Growth
+$181M
Cap. Flow
-$182M
Cap. Flow %
-9.13%
Top 10 Hldgs %
62.34%
Holding
416
New
102
Increased
87
Reduced
79
Closed
120

Top Buys

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$21.3M
2
SPY icon
State Street SPDR S&P 500 ETF Trust
SPY
+$21.2M
3
REGN icon
Regeneron Pharmaceuticals
REGN
+$16.1M
4
BIIB icon
Biogen
BIIB
+$9.79M
5
SRPT icon
Sarepta Therapeutics
SRPT
+$8.84M

Top Sells

Rank Stock Value
1
IWM icon
iShares Russell 2000 ETF
IWM
+$33.1M
2
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
+$7.45M
3
MBLY
Mobileye N.V.
MBLY
+$7.26M
4
TBRA
Tobira Therapeutics, Inc. Common Stock
TBRA
+$5.86M
5
ASXC
Asensus Surgical, Inc.
ASXC
+$5.01M

Sector Composition

Rank Sector Weight
1 Healthcare 11.94%
2 Consumer Staples 0.06%
3 Industrials 0.04%
4 Technology 0.04%
5 Materials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DERM
251
PUT
DELISTED
Dermira, Inc.
DERM
$207K 0.01%
100
– –
APEN
252
DELISTED
Apollo Endosurgery, Inc.
APEN
$206K 0.01%
14,375
– –
ASXC
253
PUT
DELISTED
Asensus Surgical, Inc.
ASXC
$205K 0.01%
+37
New +$1.58K
CLVS
254
PUT
DELISTED
Clovis Oncology, Inc.
CLVS
$192K 0.01%
+100
New +$2.12K
MNKD icon
255
PUT
MannKind Corp
MNKD
$1.28B
$176K 0.01%
219
-3,843
-95% -$22K
ARDX icon
256
Ardelyx
ARDX
$1.24B
$173K 0.01%
+22,278
New +$219K
ALDX icon
257
Aldeyra Therapeutics
ALDX
$91.7M
$172K 0.01%
41,096
-27,603
-40% -$133K
AMRN
258
PUT
Amarin Corp
AMRN
$284M
$171K 0.01%
56
– –
ARQL
259
DELISTED
Arqule Inc
ARQL
$160K 0.01%
+100,000
New +$175K
CERE
260
DELISTED
CERES, INC. COMMON STOCK NEW
CERE
$158K 0.01%
720,378
+149,459
+26% +$39.1K
SGYPW
261
DELISTED
Synergy Pharmaceuticals, Inc. - Warrants
SGYPW
$157K 0.01%
285,414
-5,892
-2% -$5.65K
NURO
262
DELISTED
NeuroMetrix, Inc. Common Stock
NURO
$154K 0.01%
132
-381
-74% -$395K
NXTM
263
PUT
DELISTED
NxStage Medical Inc.
NXTM
$150K 0.01%
+100
New +$1.68K
ARLZ
264
CALL
DELISTED
Aralez Pharmaceuticals Inc.
ARLZ
$133K 0.01%
+375
New +$1.93K
TRIL
265
DELISTED
Trillium Therapeutics Inc.
TRIL
$131K 0.01%
+14,137
New +$119K
KTOVW
266
DELISTED
Kitov Pharma Ltd. Warrants
KTOVW
$126K 0.01%
114,720
– –
NWBO
267
PUT
DELISTED
Northwest Biotherapeutics, Inc. Common stock
NWBO
$119K 0.01%
813
-352
-30% -$695
ALBO
268
DELISTED
Albireo Pharma Inc
ALBO
$118K 0.01%
11,917
-37,441
-76% -$333K
CBAY
269
DELISTED
Cymabay Therapeutics
CBAY
$91K ﹤0.01%
67,534
-526,366
-89% -$652K
AKBA icon
270
CALL
Akebia Therapeutics
AKBA
$327M
$90K ﹤0.01%
+100
New +$811
PGNX
271
PUT
DELISTED
Progenics Pharmaceuticals Inc
PGNX
$57K ﹤0.01%
+130
New +$579
ADVM
272
CALL
DELISTED
Adverum Biotechnologies
ADVM
$55K ﹤0.01%
+11
New +$614
ANTH
273
CALL
DELISTED
Anthera Pharmaceuticals, Inc.
ANTH
$55K ﹤0.01%
19
-231
-92% -$6.27K
EYEGW
274
DELISTED
Eyegate Pharmaceuticals, Inc. Warrants
EYEGW
$49K ﹤0.01%
65,393
-108,757
-62% -$75.3K
BCLI
275
CALL
DELISTED
BRAINSTORM CELL THERAPUTC
BCLI
$47K ﹤0.01%
+12
New +$441
9 10
11
12 13

Similar funds

NA
Novus Advisors Greenville, South Carolina $44.7M AUM 18.41% 1-Year Est. Return
CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

Sabby Management's Q1 2016 Portfolio in Review

As of Q1 2016, Sabby Management held 416 positions worth $2B, up 9.9% from $1.82B the previous quarter. Its ten largest holdings account for 62% of the portfolio.

Sabby Management withdrew a net $182M in Q1 2016, closing 120 positions and reducing 79 holdings. Its most notable exit was iShares Russell 2000 ETF, an estimated $33.1M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 12% of assets, up from 10% a quarter earlier, followed by Consumer Staples and Industrials.

Against the trend, Sabby Management opened a new position in Amgen worth $21.5M.

  • Sabby Management's largest Q1 2016 buy was Amgen: 143,486 shares worth $21.5M.
  • Sabby Management added most to Northwest Biotherapeutics, Inc. Common stock in Q1 2016, an estimated $4.73M increase.
  • Sabby Management's biggest Q1 2016 reduction was GW Pharmaceuticals Plc American Depositary Shares, cutting an estimated $7.45M.
  • Sabby Management fully exited iShares Russell 2000 ETF in Q1 2016, selling an estimated $33.1M.
  • Sabby Management's ten largest holdings make up 62% of its $2B portfolio in Q1 2016.
  • Sabby Management opened 102 new positions and closed 120 in Q1 2016.
  • Sabby Management's portfolio value rose 9.9% quarter-over-quarter to $2B.

Based on Sabby Management's 13F filing for Q1 2016, filed 13 May 2016.